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Objective: matrix metalloproteases (MMPs) produced by vascular smooth-muscle cells (VSMCs) degrade extracellular
matrix and facilitate the migration of these cells. This is a fundamental process in arterial intimal hyperplasia. This study
investigated whether Marimastat (a selective but non-specific MMP inhibitor) can prevent intimal hyperplasia in cultured
human internal mammary artery (IMA).
Materials and methods: segments of IMA from 8 patients were prepared and cultured for 14 days in serum-supplemented
medium (control) or in medium supplemented with Marimastat at 2 concentrations (treatment groups). The tissue was
fixed, sectioned, stained and neointimal thicknesses measured by computer-aided image analysis. Further sections were
cultured in the same manner and prepared for gel enzymography to quantify the production of MMPs.
Results: neointimal thickness was significantly reduced by Marimastat in a dose-dependent manner when compared to
controls (p=0.008 Wilcoxon). Gel enzymography demonstrated a reduction in levels of MMP2 and MMP9. This was
most significant for the active forms of the enzymes (p=0.03).
Conclusions: our results suggest that there is a potential therapeutic role for specific inhibition of the gelatinases in the
prevention of human arterial restenosis.
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Introduction (MT-MMPs), which have a transmembrane domain
and are an integral part of the plasma membrane.12
Restenosis caused by intimal hyperplasia is the most Metalloprotease latency is ensured by the presence of
common cause of failure of vascular intervention a prodomain, with activation occurring by limited
within the first postoperative year.1 Intimal hyperplasia proteolysis.13,14 In vivo, plasmin acts as the principal
(IH) is characterised by the migration of medial vas- activator of MMPs promoting cleavage of the latent
cular smooth-muscle cells (VSMCs) through the in- propeptides.15 Metalloprotease activity is regulated at
ternal elastic lamina into the arterial intima and their several levels. A number of growth factors and cyto-
subsequent proliferation to produce the intimal kines have been shown to either stimulate or inhibit
hyperplastic lesion.2–5 The lesion also consists of extra- the synthesis of MMPs by regulating transcription.16
cellular matrix (ECM)6 which must be degraded to Specific tissue inhibitors of metalloproteases (TIMPs)
allow for VSMC migration.7,8 Vascular smooth-muscle are secreted by the same cells and are important in
cells are able to produce and secrete the necessary establishing a balance between matrix synthesis and
proteases to degrade all components of the ECM.9,10 degradation.17 Matrix metalloproteases are classified
Matrix metalloproteases (MMPs) are a family of according to the specific substrate that they degrade.
zinc-dependent enzymes, which are the principal reg- The arterial basement membrane consists pre-
ulators of the ECM.11 They are produced in latent form dominantly of type IV collagen. This is degraded by
by a range of cell types including inflammatory cells, the MMPs, gelatinase A (MMP-2) and gelatinase B
fibroblasts and VSMCs. They are all secreted as pro- (MMP-9).18 These gelatinases are required by the
enzymes, except the membrane type metalloproteases VSMCs to facilitate their progress from media to intima
in the progression of IH.8 Southgate et al.7 dem-
onstrated that migration and proliferation of VSMC
* Please address all correspondence to: K. E. Porter, Department of explants from rabbit artery was inhibited by MMPSurgery, Robert Kilpatrick Clinical Sciences Building, University of
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MMPs in the remodelling which occurs after arterial elastin stain22 in order to identify the layers of the
arterial wall. An average of 30 measurements of neo-angioplasty in the rat and therefore in the restenotic
process.19,20 Both increased gelatinase secretion and intimal thickness were made on each of 2 consecutive
sections of each sample using a computer-aided imagemRNA production have been demonstrated in post-
angioplasty tissue in animal models.19 analysis system (Improvision, Coventry, U.K.) as pre-
viously described.6Although there is evidence for the role of MMPs in
IH in animal models, there is a paucity of data re-
garding human arteries. The aim of this study, there-
Gelatin enzymographyfore, was to investigate the role of MMPs in the
production of IH in an in vitro model of human arterial
Samples from six patients were prepared for metallo-intimal hyperplasia.
protease extraction in a manner previously des-
cribed.23,24 Frozen tissue samples were thawed over
ice, weighed, diced into pieces of approximately 1 mm2
Methods and then homogenised in 1 ml of buffer per 1 mg
of tissue (urea 2 mM, Tris-HCl 50 mM pH 7.6, NaCl
Culture methods 137 mM, EDTA 1 g/l, Brij-35 1 ml/l and PMSF (a serine
protease inhibitor) 0.1 mM – all supplied by Sigma,
Sections of internal mammary artery (IMA) were ob- Poole, U.K.).
tained from eight consecutive patients undergoing The homogenate was then centrifuged at 11 000 g
coronary artery bypass grafting. They were prepared for 1 hour at 4 °C and the resultant supernatant
for organ culture by a method previously described.21 dialysed against a dialysing buffer (Tris-HCl 25 mM
Briefly, segments were cleaned of their fat and ad- pH 8.5, CaCl2 10 mM, Brij-35 1 ml/l, PMSF 0.1 mM)ventitial pedicle and divided into 3 segments of ap- for 18 hours at 4 °C using 10 kDa Visking tubing
proximately 5-mm length. Each of these was then (Merck, U.K.). The protein content of each sample
opened longitudinally and laid, endothelial surface was determined using spectrophotometry and the
uppermost, in a culture dish containing pre-cast Syl- samples standardised.25 Equivalent protein loads were
gard resin (Dow Corning, Seneffe, Belgium) to which resolved on a non-reducing SDS–polyacrylamide gel
the sample was pinned. To each dish was added 5 ml impregnated with 1 mg/ml gelatin.24 Conditioned
of standard culture medium (RPMI 1640, 30% foetal medium from the HT 1080 human fibrosarcoma cell
calf serum (v/v), penicillin 50 U/ml, streptomycin line was loaded onto one lane of each gel to act as
50 lg/ml, and L-glutamine 2 mmol/l). One segment a positive control, and protein standards (BioRad,
served as a control specimen, the other two being the Hemel Hempstead, U.K.) were loaded onto another
treatment groups. In these groups the culture medium lane for estimation of the molecular weights of each
was supplemented with Marimastat at 10-6 M and band. After completion of the separation, SDS was
10-5 M concentrations. The samples were maintained removed by incubation in three consecutive washes
in a humidified cell culture incubator at 37 °C with of 2.5% Triton X-100 (3·15 min) and the gels were
5% CO2 in air for 14 days. The medium and drug were then incubated at 37 °C for 18 h in incubation buffer
renewed every 2–3 days. At the end of the 14-day (50 mM Tris-HCl, 10 mM CaCl2 and 0.05% Brij-35,culture period each sample was fixed in 4% para- pH 7.4). Inhibition of protease activity was used to
formaldehyde for 18 hours, processed, paraffin-em- confirm the nature of the protease being detected on
bedded and sectioned to 4-lm thickness. the zymograms. EDTA (20 mM), 1,10 phenanthroline
A further six samples from consecutive patients (5 mM) or PMSF (1 mM) was included in the in-
were prepared in exactly the same manner as above, cubation buffer to verify the presence of specific
and after completion of a 14-day culture period each MMPs. Following incubation, the gels were fixed
specimen was immediately snap-frozen in liquid nitro- and stained in 0.1% Coomassie blue R250 (in 50%
gen and stored at -80 °C for subsequent processing methanol/20% acetic acid/30% double-distilled
and metalloprotease extraction. water) for 2–3 hours. Proteinases were visualised as
clear bands of lysis against a dark background of
substrate. The molecular weight of each band was
estimated by comparison against positions of knownImmunohistochemistry
molecular weight standards. The relative density of
each band was determined from negative pho-Sections of 4-lm thickness were stained using a com-
bined monoclonal anti-smooth-muscle actin/Miller’s tographic images of the gels with a Pharmacia LKB
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Imagemaster scanning densitometer (Pharmacia LKB,
St Albans, Herts., U.K.) and was expressed as a
product of the optical density and area of the band.
Previous experiments (data not shown) demonstrated
that the protein concentration used in this analysis
was within the range for densitometric quantification.
Paired treatment samples and their controls were
run on the same gels. The product of the optical
density and area of the band was compared to the
HT 1080 control (same sample for each gel) to obtain
a ratio that could be compared between gels. No
direct comparison was made between different gels.
Western blotting experiments (data not shown) con-
firmed that the bands corresponded to MMP-2 and
MMP-9.
Fig. 1. Scatter plot to show measurements of neointimal thickness
of control and Marimastat-treated arteries. Horizontal bars indicate
median and 95% confidence intervals.
Statistics
Measurements of neointimal thickness are expressed
as median and 95% CI. Differences between treatment
groups were analysed using the Wilcoxon paired-
rank test, and significance was assumed at the 95%
confidence level. For the zymographic analysis, the Gelatin zymography
relative density was quantified and compared between
samples run on the same gel. Values are expressed as Densitometric values are expressed as a percentage of
median and 95% CI as a percentage of HT 1080 control control (HT 1080 cell line). For latent MMP-9, the
value. Differences between groups were analysed median value for the control group was 100% (95%
using the Wilcoxon paired-rank test. All statistical CI 89–111). For Marimastat at 10-5 M, the median value
analyses in this study were performed using the com- was 70% (95% CI 58–91) (p=0.05). At 10-6 M, the
puter software package SPSS 8.0 for Windows. median value was 69% (95% CI 45–90) (p=0.03). For
active MMP-9, the median value for the control group
was 100% (95% CI 73–151). At 10-5 M Marimastat the
median value was 42% (95% CI 21–64) (p=0.03) and
at 10-6 M the median was 48% (95% CI 30–64) (p=Results
0.03).
For latent MMP-2, the median densitometric valueNeointimal thickness
for the control group was 109% (95% CI 83–126). For
Marimastat at 10-5 M, the median value was 89% (95%During the 14-day culture period, all control specimens
developed a significant neointimal layer with a median CI 54–117) (p=0.03) and at 10-6 M the median value
was 85.7% (95% CI 61.9–101.2) (p=0.03). For activethickness of 5.5 (95% CI 4.2–7.1) lm. Median neo-
intimal thickness in artery treated with Marimastat at MMP-2, the median value for the control group was
139% (95% CI 127–161). At 10-5 M Marimastat, the10-5 M was 0.75 (95% CI 0.5–1.2) lm, (p=0.008). At
10-6 M concentration, the median neointimal thickness median value was 68% (95% CI 41–85) (p=0.03) and
at 10-6 M the median value was 74% (95% CI 64–84)was 1.7 (95% CI 1.3–2.7) lm (p=0.008). These results
are summarised in Figure 1. A representative histo- (p=0.03). These results are summarised in Figure 3.
A representative gelatin zymogram for segmentslogical section of internal mammary artery cultured
in the absence and presence of Marimastat at each of internal mammary artery cultured both with and
without Marimastat at each concentration is shown inconcentration is shown in Fig. 2(a and b). CD 31
staining (Fig. 2c) confirmed the retention of an intact Figure 4 within the molecular weight range
60–100 kDa. No other bands outside this range wereendothelium on the arterial segments after the culture
period. detected (up to 250 kDa).
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Fig. 2. Histological sections of cultured internal mammary artery
stained with a combined smooth-muscle actin and Miller’s elastin
stain, showing the development of a neointima (arrowed) in rep-
resentative segments from (a) control, and (b) Marimastat-treated
artery. IEL=internal elastic lamina, M-media, A=adventitia. CD 31
staining (c) demonstrates the presence of intact endothelium at the
end of the culture period (arrow).
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Fig. 3. Scatter plots showing the protease activity of cultured IMA homogenates for (a) MMP-9 and (b) MMP-2. Horizontal bars represent
the median and 95% confidence intervals.
Fig. 4. Representative gelatin zymogram for paired control and Marimastat-treated arterial segments. Fibrosarcoma-derived HT-1080 cells
served as positive controls.
Discussion of MMPs was detected by immunohistochemistry and
found to be predominantly localised to the endo-
The study clearly demonstrates that Marimastat, in thelium and neointimal smooth-muscle cells, and in
the smooth-muscle cells adjacent to the internal elastictherapeutic doses, is able to significantly reduce the
formation of neointima in this laboratory model of lamina.27
Southgate et al.28 demonstrated increased levels ofhuman arterial IH. This attenuation in the thickness
of the neointima is accompanied by a reduction in the MMP-2 and MMP-9 in arterial tissue damaged by bal-
loon angioplasty in pigs compared with untreated con-tissue levels of MMP-2 and MMP-9. Previous work in
this laboratory in cultured human saphenous vein has trol segments. Similar findings have also been
demonstrated in a rat model of angioplasty.19 However,demonstrated that Marimastat reduces both neointima
formation and the tissue levels of both latent MMP-2 although the use of peptide MMP inhibitors reduced
MMP activity in the rat model, neointima formationand MMP-9 detected by gel zymography.26 Production
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after a 2-week period was not significantly attenuated.20 for clinical trials investigating the effect of MMP in-
hibition on arterial restenosis in the clinical setting.This catch-up phenomenon was not observed in our
study, perhaps because of the time period involved, but
possiblybecause thehumantissueculture lesion ismore
akin to the human arterial restenosis lesion in being
Acknowledgementsless cellular and containing more ECM than the lesion
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